Everflex Topical Analgesic Pain Relief with Msm

Description

Everflex Topical Analgesic Pain Relief Cream is formulated with Methylsulfonylmethane (MSM) as an active ingredient. This product is presented in a dosage form of a cream, contained within a 2 fluid ounce (58.7 mL) tube. The cream is designed for topical application to provide analgesic relief.

Uses and Indications

This drug is indicated for use in specific patient populations as determined by clinical guidelines. Currently, there are no detailed indications or usage specifications provided. Healthcare professionals are advised to refer to the latest clinical data and guidelines to determine appropriate applications for this drug. There are no known teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 2 years and older, the recommended application is to the affected area not more than 3 to 4 times per day. It is important to ensure that the application is limited to the specified frequency to avoid potential adverse effects.

For children under 2 years of age, it is advised to consult a physician prior to use to determine the appropriate course of action and ensure safety.

Contraindications

There are no specific contraindications listed for this product. However, it is advised to keep the product out of reach of children to prevent accidental ingestion or misuse.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes to prevent irritation or injury. In the event of accidental contact with the eyes, immediate rinsing with water is recommended, and medical attention should be sought if irritation persists.

Healthcare professionals should ensure that patients are informed of these warnings to promote safe usage and minimize the risk of adverse effects. Regular monitoring of the patient's response to treatment may be warranted, although specific laboratory tests have not been indicated in the provided information.

In case of any concerning symptoms or adverse reactions, patients should be advised to discontinue use and consult their healthcare provider promptly. Emergency medical assistance should be sought if severe reactions occur.

Side Effects

Patients should be aware that the product is for external use only and must avoid contact with the eyes. Serious adverse reactions have not been reported in clinical trials; however, caution is advised to prevent any potential irritation or adverse effects associated with improper use.

In postmarketing experiences, there have been no significant findings that indicate a pattern of serious adverse reactions. Nonetheless, it is essential for patients to adhere to the recommended guidelines to minimize the risk of adverse effects.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Everflex Topical Analgesic Pain Relief with Msm (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be kept out of reach of children. For children under 2 years of age, consultation with a physician is advised prior to use. In patients aged 2 years and older, the medication may be applied to the affected area no more than 3 to 4 times per day.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There are no specific warnings or precautions regarding the use of Everflex Topical Analgesic Pain Relief with MSM during pregnancy. The available data does not indicate whether the product is contraindicated in pregnant patients or if there are any associated risks to the fetus. Additionally, no dosage modifications or special precautions for individuals who are pregnant are provided. Healthcare professionals should consider the absence of data when advising women of childbearing potential regarding the use of this product during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of Everflex Topical Analgesic Pain Relief with MSM in lactating mothers. Additionally, there is no information available concerning the potential for excretion of the product in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized to ensure patient safety and mitigate potential complications associated with overdose.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are provided in the insert for Everflex Topical Analgesic Pain Relief with MSM.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the necessity of proper storage and handling to ensure the safety of young individuals.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light to protect its quality. After opening, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with a recommended application frequency of no more than 3 to 4 times per day to the affected area. Clinicians should advise patients to keep the product out of reach of children and to discontinue use if the condition worsens, if symptoms persist for more than 7 days, or if symptoms clear up and then recur within a few days. It is important to instruct patients not to apply the product to wounds or damaged skin, to avoid tight bandaging, and to use it for external purposes only. Additionally, patients should be cautioned to avoid contact with the eyes.

Drug Information (PDF)

This file contains official product information for Everflex Topical Analgesic Pain Relief with Msm, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)